Review



small airway epithelial cell growth medium  (PromoCell)


Bioz Verified Symbol PromoCell is a verified supplier
Bioz Manufacturer Symbol PromoCell manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 95
      Buy from Supplier

    Structured Review

    PromoCell small airway epithelial cell growth medium
    BCL XL ‐PROTAC induces potent proteasomal degradation of BCL XL protein in human SAECs and shows high selectivity over BCL 2 degradation. Healthy small airway <t>epithelial</t> cells were treated with 10 −12 to 10 −4 M of BCL XL ‐PROTAC for 24 h. (a) BCL XL degradation by BCL XL ‐PROTAC via CRBN binder and MG132. (b) Protein levels of BCL XL and BCL 2 were measured in the cell lysates and the percentage of degradation, and the half maximal degradation concentration (DC 50 ) were calculated. (c) Cells were treated with BCL XL ‐PROTAC and 3 μM of the proteasome inhibitor MG132 or with a CRBN binder to compete with the E3 ligase binding. BCL XL degradation was measured in cell lysates and expressed as percentage of degradation and DC 50 . Plotted data are represented as mean +/− standard deviation of 3 independent experiments, each with 2 technical duplicates. 0% degradation indicate levels detected in vehicle/DMSO‐treated cells, and 100% degradation indicate no detectable BCL XL protein (= medium control).
    Small Airway Epithelial Cell Growth Medium, supplied by PromoCell, used in various techniques. Bioz Stars score: 95/100, based on 98 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/small airway epithelial cell growth medium/product/PromoCell
    Average 95 stars, based on 98 article reviews
    small airway epithelial cell growth medium - by Bioz Stars, 2026-06
    95/100 stars

    Images

    1) Product Images from "Clearance of Senescent Cells by BCL XL ‐ PROTAC : A Novel Approach to Treat COPD ?"

    Article Title: Clearance of Senescent Cells by BCL XL ‐ PROTAC : A Novel Approach to Treat COPD ?

    Journal: Aging Cell

    doi: 10.1111/acel.70487

    BCL XL ‐PROTAC induces potent proteasomal degradation of BCL XL protein in human SAECs and shows high selectivity over BCL 2 degradation. Healthy small airway epithelial cells were treated with 10 −12 to 10 −4 M of BCL XL ‐PROTAC for 24 h. (a) BCL XL degradation by BCL XL ‐PROTAC via CRBN binder and MG132. (b) Protein levels of BCL XL and BCL 2 were measured in the cell lysates and the percentage of degradation, and the half maximal degradation concentration (DC 50 ) were calculated. (c) Cells were treated with BCL XL ‐PROTAC and 3 μM of the proteasome inhibitor MG132 or with a CRBN binder to compete with the E3 ligase binding. BCL XL degradation was measured in cell lysates and expressed as percentage of degradation and DC 50 . Plotted data are represented as mean +/− standard deviation of 3 independent experiments, each with 2 technical duplicates. 0% degradation indicate levels detected in vehicle/DMSO‐treated cells, and 100% degradation indicate no detectable BCL XL protein (= medium control).
    Figure Legend Snippet: BCL XL ‐PROTAC induces potent proteasomal degradation of BCL XL protein in human SAECs and shows high selectivity over BCL 2 degradation. Healthy small airway epithelial cells were treated with 10 −12 to 10 −4 M of BCL XL ‐PROTAC for 24 h. (a) BCL XL degradation by BCL XL ‐PROTAC via CRBN binder and MG132. (b) Protein levels of BCL XL and BCL 2 were measured in the cell lysates and the percentage of degradation, and the half maximal degradation concentration (DC 50 ) were calculated. (c) Cells were treated with BCL XL ‐PROTAC and 3 μM of the proteasome inhibitor MG132 or with a CRBN binder to compete with the E3 ligase binding. BCL XL degradation was measured in cell lysates and expressed as percentage of degradation and DC 50 . Plotted data are represented as mean +/− standard deviation of 3 independent experiments, each with 2 technical duplicates. 0% degradation indicate levels detected in vehicle/DMSO‐treated cells, and 100% degradation indicate no detectable BCL XL protein (= medium control).

    Techniques Used: Concentration Assay, Binding Assay, Standard Deviation, Control



    Similar Products

    small airway epithelial cell growth medium  (PromoCell)
    95
    PromoCell small airway epithelial cell growth medium
    BCL XL ‐PROTAC induces potent proteasomal degradation of BCL XL protein in human SAECs and shows high selectivity over BCL 2 degradation. Healthy small airway <t>epithelial</t> cells were treated with 10 −12 to 10 −4 M of BCL XL ‐PROTAC for 24 h. (a) BCL XL degradation by BCL XL ‐PROTAC via CRBN binder and MG132. (b) Protein levels of BCL XL and BCL 2 were measured in the cell lysates and the percentage of degradation, and the half maximal degradation concentration (DC 50 ) were calculated. (c) Cells were treated with BCL XL ‐PROTAC and 3 μM of the proteasome inhibitor MG132 or with a CRBN binder to compete with the E3 ligase binding. BCL XL degradation was measured in cell lysates and expressed as percentage of degradation and DC 50 . Plotted data are represented as mean +/− standard deviation of 3 independent experiments, each with 2 technical duplicates. 0% degradation indicate levels detected in vehicle/DMSO‐treated cells, and 100% degradation indicate no detectable BCL XL protein (= medium control).
    Small Airway Epithelial Cell Growth Medium, supplied by PromoCell, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/small airway epithelial cell growth medium/product/PromoCell
    Average 95 stars, based on 1 article reviews
    small airway epithelial cell growth medium - by Bioz Stars, 2026-06
    95/100 stars
    		  Buy from Supplier
    hsaepc cells  (PromoCell)
    95
    PromoCell hsaepc cells
    BCL XL ‐PROTAC induces potent proteasomal degradation of BCL XL protein in human SAECs and shows high selectivity over BCL 2 degradation. Healthy small airway <t>epithelial</t> cells were treated with 10 −12 to 10 −4 M of BCL XL ‐PROTAC for 24 h. (a) BCL XL degradation by BCL XL ‐PROTAC via CRBN binder and MG132. (b) Protein levels of BCL XL and BCL 2 were measured in the cell lysates and the percentage of degradation, and the half maximal degradation concentration (DC 50 ) were calculated. (c) Cells were treated with BCL XL ‐PROTAC and 3 μM of the proteasome inhibitor MG132 or with a CRBN binder to compete with the E3 ligase binding. BCL XL degradation was measured in cell lysates and expressed as percentage of degradation and DC 50 . Plotted data are represented as mean +/− standard deviation of 3 independent experiments, each with 2 technical duplicates. 0% degradation indicate levels detected in vehicle/DMSO‐treated cells, and 100% degradation indicate no detectable BCL XL protein (= medium control).
    Hsaepc Cells, supplied by PromoCell, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/hsaepc cells/product/PromoCell
    Average 95 stars, based on 1 article reviews
    hsaepc cells - by Bioz Stars, 2026-06
    95/100 stars
    		  Buy from Supplier
    sagmtm small airway epithelial cell growth medium bullet kit  (PromoCell)
    95
    PromoCell sagmtm small airway epithelial cell growth medium bullet kit
    BCL XL ‐PROTAC induces potent proteasomal degradation of BCL XL protein in human SAECs and shows high selectivity over BCL 2 degradation. Healthy small airway <t>epithelial</t> cells were treated with 10 −12 to 10 −4 M of BCL XL ‐PROTAC for 24 h. (a) BCL XL degradation by BCL XL ‐PROTAC via CRBN binder and MG132. (b) Protein levels of BCL XL and BCL 2 were measured in the cell lysates and the percentage of degradation, and the half maximal degradation concentration (DC 50 ) were calculated. (c) Cells were treated with BCL XL ‐PROTAC and 3 μM of the proteasome inhibitor MG132 or with a CRBN binder to compete with the E3 ligase binding. BCL XL degradation was measured in cell lysates and expressed as percentage of degradation and DC 50 . Plotted data are represented as mean +/− standard deviation of 3 independent experiments, each with 2 technical duplicates. 0% degradation indicate levels detected in vehicle/DMSO‐treated cells, and 100% degradation indicate no detectable BCL XL protein (= medium control).
    Sagmtm Small Airway Epithelial Cell Growth Medium Bullet Kit, supplied by PromoCell, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/sagmtm small airway epithelial cell growth medium bullet kit/product/PromoCell
    Average 95 stars, based on 1 article reviews
    sagmtm small airway epithelial cell growth medium bullet kit - by Bioz Stars, 2026-06
    95/100 stars
    		  Buy from Supplier
    v v supplement mix promocell  (PromoCell)
    95
    PromoCell v v supplement mix promocell
    BCL XL ‐PROTAC induces potent proteasomal degradation of BCL XL protein in human SAECs and shows high selectivity over BCL 2 degradation. Healthy small airway <t>epithelial</t> cells were treated with 10 −12 to 10 −4 M of BCL XL ‐PROTAC for 24 h. (a) BCL XL degradation by BCL XL ‐PROTAC via CRBN binder and MG132. (b) Protein levels of BCL XL and BCL 2 were measured in the cell lysates and the percentage of degradation, and the half maximal degradation concentration (DC 50 ) were calculated. (c) Cells were treated with BCL XL ‐PROTAC and 3 μM of the proteasome inhibitor MG132 or with a CRBN binder to compete with the E3 ligase binding. BCL XL degradation was measured in cell lysates and expressed as percentage of degradation and DC 50 . Plotted data are represented as mean +/− standard deviation of 3 independent experiments, each with 2 technical duplicates. 0% degradation indicate levels detected in vehicle/DMSO‐treated cells, and 100% degradation indicate no detectable BCL XL protein (= medium control).
    V V Supplement Mix Promocell, supplied by PromoCell, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/v v supplement mix promocell/product/PromoCell
    Average 95 stars, based on 1 article reviews
    v v supplement mix promocell - by Bioz Stars, 2026-06
    95/100 stars
    		  Buy from Supplier
    bovine pituitary extract promocell suppl  (PromoCell)
    95
    PromoCell bovine pituitary extract promocell suppl
    BCL XL ‐PROTAC induces potent proteasomal degradation of BCL XL protein in human SAECs and shows high selectivity over BCL 2 degradation. Healthy small airway <t>epithelial</t> cells were treated with 10 −12 to 10 −4 M of BCL XL ‐PROTAC for 24 h. (a) BCL XL degradation by BCL XL ‐PROTAC via CRBN binder and MG132. (b) Protein levels of BCL XL and BCL 2 were measured in the cell lysates and the percentage of degradation, and the half maximal degradation concentration (DC 50 ) were calculated. (c) Cells were treated with BCL XL ‐PROTAC and 3 μM of the proteasome inhibitor MG132 or with a CRBN binder to compete with the E3 ligase binding. BCL XL degradation was measured in cell lysates and expressed as percentage of degradation and DC 50 . Plotted data are represented as mean +/− standard deviation of 3 independent experiments, each with 2 technical duplicates. 0% degradation indicate levels detected in vehicle/DMSO‐treated cells, and 100% degradation indicate no detectable BCL XL protein (= medium control).
    Bovine Pituitary Extract Promocell Suppl, supplied by PromoCell, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/bovine pituitary extract promocell suppl/product/PromoCell
    Average 95 stars, based on 1 article reviews
    bovine pituitary extract promocell suppl - by Bioz Stars, 2026-06
    95/100 stars
    		  Buy from Supplier
    hydrocortisone promocell suppl  (PromoCell)
    95
    PromoCell hydrocortisone promocell suppl
    BCL XL ‐PROTAC induces potent proteasomal degradation of BCL XL protein in human SAECs and shows high selectivity over BCL 2 degradation. Healthy small airway <t>epithelial</t> cells were treated with 10 −12 to 10 −4 M of BCL XL ‐PROTAC for 24 h. (a) BCL XL degradation by BCL XL ‐PROTAC via CRBN binder and MG132. (b) Protein levels of BCL XL and BCL 2 were measured in the cell lysates and the percentage of degradation, and the half maximal degradation concentration (DC 50 ) were calculated. (c) Cells were treated with BCL XL ‐PROTAC and 3 μM of the proteasome inhibitor MG132 or with a CRBN binder to compete with the E3 ligase binding. BCL XL degradation was measured in cell lysates and expressed as percentage of degradation and DC 50 . Plotted data are represented as mean +/− standard deviation of 3 independent experiments, each with 2 technical duplicates. 0% degradation indicate levels detected in vehicle/DMSO‐treated cells, and 100% degradation indicate no detectable BCL XL protein (= medium control).
    Hydrocortisone Promocell Suppl, supplied by PromoCell, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/hydrocortisone promocell suppl/product/PromoCell
    Average 95 stars, based on 1 article reviews
    hydrocortisone promocell suppl - by Bioz Stars, 2026-06
    95/100 stars
    		  Buy from Supplier
    triiodo l thyronine promocell suppl  (PromoCell)
    95
    PromoCell triiodo l thyronine promocell suppl
    BCL XL ‐PROTAC induces potent proteasomal degradation of BCL XL protein in human SAECs and shows high selectivity over BCL 2 degradation. Healthy small airway <t>epithelial</t> cells were treated with 10 −12 to 10 −4 M of BCL XL ‐PROTAC for 24 h. (a) BCL XL degradation by BCL XL ‐PROTAC via CRBN binder and MG132. (b) Protein levels of BCL XL and BCL 2 were measured in the cell lysates and the percentage of degradation, and the half maximal degradation concentration (DC 50 ) were calculated. (c) Cells were treated with BCL XL ‐PROTAC and 3 μM of the proteasome inhibitor MG132 or with a CRBN binder to compete with the E3 ligase binding. BCL XL degradation was measured in cell lysates and expressed as percentage of degradation and DC 50 . Plotted data are represented as mean +/− standard deviation of 3 independent experiments, each with 2 technical duplicates. 0% degradation indicate levels detected in vehicle/DMSO‐treated cells, and 100% degradation indicate no detectable BCL XL protein (= medium control).
    Triiodo L Thyronine Promocell Suppl, supplied by PromoCell, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/triiodo l thyronine promocell suppl/product/PromoCell
    Average 95 stars, based on 1 article reviews
    triiodo l thyronine promocell suppl - by Bioz Stars, 2026-06
    95/100 stars
    		  Buy from Supplier
    epinephrine promocell suppl  (PromoCell)
    95
    PromoCell epinephrine promocell suppl
    BCL XL ‐PROTAC induces potent proteasomal degradation of BCL XL protein in human SAECs and shows high selectivity over BCL 2 degradation. Healthy small airway <t>epithelial</t> cells were treated with 10 −12 to 10 −4 M of BCL XL ‐PROTAC for 24 h. (a) BCL XL degradation by BCL XL ‐PROTAC via CRBN binder and MG132. (b) Protein levels of BCL XL and BCL 2 were measured in the cell lysates and the percentage of degradation, and the half maximal degradation concentration (DC 50 ) were calculated. (c) Cells were treated with BCL XL ‐PROTAC and 3 μM of the proteasome inhibitor MG132 or with a CRBN binder to compete with the E3 ligase binding. BCL XL degradation was measured in cell lysates and expressed as percentage of degradation and DC 50 . Plotted data are represented as mean +/− standard deviation of 3 independent experiments, each with 2 technical duplicates. 0% degradation indicate levels detected in vehicle/DMSO‐treated cells, and 100% degradation indicate no detectable BCL XL protein (= medium control).
    Epinephrine Promocell Suppl, supplied by PromoCell, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/epinephrine promocell suppl/product/PromoCell
    Average 95 stars, based on 1 article reviews
    epinephrine promocell suppl - by Bioz Stars, 2026-06
    95/100 stars
    		  Buy from Supplier

    Image Search Results


    BCL XL ‐PROTAC induces potent proteasomal degradation of BCL XL protein in human SAECs and shows high selectivity over BCL 2 degradation. Healthy small airway epithelial cells were treated with 10 −12 to 10 −4 M of BCL XL ‐PROTAC for 24 h. (a) BCL XL degradation by BCL XL ‐PROTAC via CRBN binder and MG132. (b) Protein levels of BCL XL and BCL 2 were measured in the cell lysates and the percentage of degradation, and the half maximal degradation concentration (DC 50 ) were calculated. (c) Cells were treated with BCL XL ‐PROTAC and 3 μM of the proteasome inhibitor MG132 or with a CRBN binder to compete with the E3 ligase binding. BCL XL degradation was measured in cell lysates and expressed as percentage of degradation and DC 50 . Plotted data are represented as mean +/− standard deviation of 3 independent experiments, each with 2 technical duplicates. 0% degradation indicate levels detected in vehicle/DMSO‐treated cells, and 100% degradation indicate no detectable BCL XL protein (= medium control).

    Journal: Aging Cell

    Article Title: Clearance of Senescent Cells by BCL XL ‐ PROTAC : A Novel Approach to Treat COPD ?

    doi: 10.1111/acel.70487

    Figure Lengend Snippet: BCL XL ‐PROTAC induces potent proteasomal degradation of BCL XL protein in human SAECs and shows high selectivity over BCL 2 degradation. Healthy small airway epithelial cells were treated with 10 −12 to 10 −4 M of BCL XL ‐PROTAC for 24 h. (a) BCL XL degradation by BCL XL ‐PROTAC via CRBN binder and MG132. (b) Protein levels of BCL XL and BCL 2 were measured in the cell lysates and the percentage of degradation, and the half maximal degradation concentration (DC 50 ) were calculated. (c) Cells were treated with BCL XL ‐PROTAC and 3 μM of the proteasome inhibitor MG132 or with a CRBN binder to compete with the E3 ligase binding. BCL XL degradation was measured in cell lysates and expressed as percentage of degradation and DC 50 . Plotted data are represented as mean +/− standard deviation of 3 independent experiments, each with 2 technical duplicates. 0% degradation indicate levels detected in vehicle/DMSO‐treated cells, and 100% degradation indicate no detectable BCL XL protein (= medium control).

    Article Snippet: Primary small airway epithelial cells (SAEC) were cultured as monolayers in Small Airway Epithelial Cell Growth Medium (Promocell, Germany) on collagen (1% w/v) coated plates (Devulder et al. ).

    Techniques: Concentration Assay, Binding Assay, Standard Deviation, Control